COMPARE · Reviewed July 9, 2026
ADMA vs ANIP
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 86.9, ANIP scored 83.7 — ADMA leads.
Compare another set
ADMA
ADMA Biologics, Inc.
86.9
$9.27 · $2.1B
Score gap
3.2
ADMA leads
ANIP
ANI Pharmaceuticals, Inc.
83.7
$83.78 · $1.9B
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
ANIP
81
Qualityreturns · margins · balance sheet
64
100
Growthrevenue & earnings expansion
100
81
Valuevaluation vs sector peers
91
ADMA and ANIP split the three pillars evenly.
Fundamentals, head-to-head
ADMA
ANIP
$108mC
FCF
$191mC
+19.6%B+
Rev
+43.8%A
1.11C
D/E
1.12C
13.6xA-
P/E
21.4xB+
0.69A-
PEG
0.49A
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
ANIP
31% below
Price vs fair valuelower is cheaper
47% below
+12%
1-yr DCF upside
+64%
+44%
5-yr DCF upside
+89%
+110%
10-yr DCF upside
+132%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
ANIP
No notable signals flagged.
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.1b. Down 55% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.69 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $17.60 (implying +90% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.9b. 16% off the 52-week high of $99.50. Revenue growing +44% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $112.71 (implying +35% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.